ARWR241220P16000
- 0.05
- 0.000.00%
Arrowhead Pharmaceuticals Newsroom
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $45
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), Arrowhead Pharmaceuticals (ARWR) and Heron Therapeutics (HRTX)
Arrowhead Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Arrowhead Pharmaceuticals Price Target Raised to $80.00/Share From $60.00 by HC Wainwright & Co.
Arrowhead Pharma Analyst Ratings
Bernstein Maintains Market Perform on Arrowhead Pharma, Lowers Price Target to $24
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR) and Sanofi (OtherSNYNF)
Arrowhead Pharmaceuticals Is Maintained at Neutral by Citigroup
RBC Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $42
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Cuts Target Price to $45
A Quick Look at Today's Ratings for Arrowhead Pharmaceuticals(ARWR.US), With a Forecast Between $26 to $45
Arrowhead Pharma Analyst Ratings
Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target
RBC Capital Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
Hold Rating on Arrowhead Pharmaceuticals: Balancing Strategic Advancements With Execution Risks
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $60
Arrowhead Pharmaceuticals Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
Arrowhead Pharma Analyst Ratings
Arrowhead Pharmaceuticals' Potential Approval of Clozasiran Drives Buy Rating and $60 Price Target
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $62